Letters to the Editor
- Maria Kelly, Madlen Gazarian, John McPhee
- Aust Prescr 2005;28:5-7
- 1 February 2005
- DOI: 10.18773/austprescr.2005.005
The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.
Editor, – Roger Goucke calls for Australian Prescriber to clarify the situation with regard to off-label prescribing (Aust Prescr 2004;27:82-3). NSW Therapeutic Advisory Group (NSW TAG)* has recently released a discussion paper to guide clinicians, policy makers and funders of health care in systematically evaluating the appropriateness of medicines proposed for off-label use.
In calling for clarification, Dr Goucke focuses his concerns on the legal issues associated with off-label use of medicines. Neither the Therapeutic Goods Administration in Australia nor the Food and Drug Administration in the USA1 regulate the use (including administration) of a medicine once it has been supplied by a product sponsor. Therefore off-label use by a practitioner (who was not a sponsor of the medicine) does not appear to be in breach of the Therapeutic Goods Act 1989 (Commonwealth) or the US Federal Food, Drug, and Cosmetic Act, 52 Stat. 1040. Although this has not been tested in an Australian court, it has been tested in US courts and found not to breach US legislation.2
In addition to legal issues, however, clinical and ethical issues, including patient consent, also need to be considered in any decision to prescribe medicines off-label. The NSW TAG Discussion Paper highlights these issues and provides a systematic approach to addressing them. The paper may be accessed on NSW TAG's web site www.nswtag.org.au
* NSW TAG is an independent, incorporated association of clinical pharmacologists, pharmacists and clinicians committed to promoting quality use of medicines in public hospitals and the wider community.
New South Wales Therapeutic Advisory Group (NSW TAG)
Senior Lecturer, School of Women's and Children's Health
University of New South Wales
Paediatric Clinical Pharmacologist and Rheumatologist
Sydney Children's Hospital, Randwick
Honorary Associate and Honorary Senior Lecturer
Centre for Values, Ethics and Law in Medicine
University of Sydney
Executive Officer, New South Wales Therapeutic Advisory Group (NSW TAG)
Senior Lecturer, School of Women's and Children's Health, University of New South Wales
Paediatric Clinical Pharmacologist and Rheumatologist, Sydney Children's Hospital, Randwick
Legal Academic Honorary Associate and Honorary Senior Lecturer Centre for Values, Ethics and Law in Medicine, University of Sydney